

at least 90% of that of average normal human plasma used as a standard and set at 100%.

26. Factor IX protein according to claim 25 having a specific activity of 100%.

Conceded
27. A method of treating human patients suffering from a deficiency of factor IX, said method comprising the step of administering to the patient a biologically active recombinant DNA-derived factor IX protein which (1) is the product of expression of cDNA encoding factor IX from a single allelic form, (2) has essentially the amino acid sequence of native human factor IX protein and retains the monomorphism of the cDNA allele, (3) is free from contamination by poxviruses and by all human plasma constituents, and (4) has a specific activity, defined as the ratio of the concentration of test sample required to clot a given volume of factor IX-deficient plasma in a given time by the kaolin-cephalin method divided by the concentration of factor IX protein in the test sample as determined by ELISA, of at least 90% of that of average normal human plasma used as a standard and set at 100%.

28. A method according to claim 27, wherein the factor IX protein has a specific activity of 100%.--